Abstract:Background: Germline pathogenic variants impairing the caspase recruitment domain family member 11 (CARD11)-B cell chronic lymphocytic leukemia/lymphoma 10 (BCL10)-MALT1 paracaspase (MALT1) (CBM) complex are associated with diverse human diseases including combined immunodeficiency (CID), atopy, and lymphoproliferation. However, the impact of CARD11 deficiency on human B-cell development, signaling, and function is incompletely understood. Objectives: This study sought to determine the cellular, immunological, and biochemical basis of disease for 2 unrelated patients who presented with profound CID associated with viral and fungal respiratory infections, interstitial lung disease, and severe colitis. Methods: Patients underwent next-generation sequencing, immunophenotyping by flow cytometry, signaling assays by immunoblot, and transcriptome profiling by RNA-sequencing. Results: Both patients carried identical novel pathogenic biallelic loss-of-function variants in CARD11 (c.2509C>T; p.Arg837∗) leading to undetectable protein expression. This variant prevented CBM complex formation, severely impairing the activation of nuclear factor-κB, c-Jun N-terminal kinase, and MALT1 paracaspase activity in B and T cells. This functional defect resulted in a developmental block in B cells at the naive and type 1 transitional B-cell stage and impaired circulating T follicular helper cell (cTFH) development, which was associated with impaired antibody responses and absent germinal center structures on lymph node histology. Transcriptomics indicated that CARD11-dependent signaling is essential for immune signaling pathways involved in the development of these cells. Both patients underwent hematopoietic stem cell transplantations, which led to functional normalization. Conclusions: Complete human CARD11 deficiency causes profound CID by impairing naive/type 1 B-cell and cTFH cell development and abolishing activation of MALT1 paracaspase, NF-κB, and JNK activity. Hematopoietic stem cell transplantation functionally restores impaired signaling pathways.

A human immunodeficiency syndrome caused by mutations in CARMIL2

CARMIL2 Immunodeficiency with Epstein Barr Virus Associated Smooth Muscle Tumor (EBV-SMT). Report of a Case with Comprehensive Review of Literature

Human CARMIL2 deficiency underlies a broader immunological and clinical phenotype than CD28 deficiency

Case report: Primary immunodeficiency due to a novel mutation in CARMIL2 and its response to combined immunomodulatory therapy

Evolution and long‐term outcomes of combined immunodeficiency due to CARMIL2 deficiency

Profound immunodeficiency with severe skin disease explained by concomitant novel CARMIL2 and PLEC1 loss-of-function mutations

Exogenous interleukin-2 can rescue in-vitro T cell activation and proliferation in patients with a novel capping protein regulator and myosin 1 linker 2 mutation

Novel CARMIL2 loss-of-function variants are associated with pediatric inflammatory bowel disease

Novel CARMIL2 (RLTPR) Mutation Presenting with Hyper-IgE and Eosinophilia: A Case Report

Inherited immunodeficiencies associated with proximal and distal defects in T cell receptor signaling and co-signaling

CARMIL2-related immunodeficiency manifesting with photosensitivity

Mechanistic understanding of the combined immunodeficiency in complete human CARD11 deficiency

A multimorphic mutation in IRF4 causes human autosomal dominant combined immunodeficiency

CARMIL2 Deficiency Presenting as Very Early Onset Inflammatory Bowel Disease

A Unique Presentation of Infantile-Onset Colitis and Eosinophilic Disease without Recurrent Infections Resulting from a Novel Homozygous CARMIL2 Variant

Dual T Cell– and B Cell–intrinsic Deficiency in Humans with Biallelic RLTPR Mutations

Germline TET2 loss of function causes childhood immunodeficiency and lymphoma

Inherited human c-Rel deficiency disrupts myeloid and lymphoid immunity to multiple infectious agents

Human interleukin-2 receptor β mutations associated with defects in immunity and peripheral tolerance

Signaling pathways involved in the T-cell-mediated immunity against Epstein-Barr virus: Lessons from genetic diseases

Dominant Combined Immunodeficiency Associated With A Heterozygous Intragenic Deletion In Irf4.